Sunitinib is a tyrosine kinase inhibitor and also inhibits VEGF and PGF improves survival in advanced pancreatic neuroendocrine tumors.
Feb 2011 NEJM
The trial had 171 patients with advanced disease, The patients were randomized to receive placebo or Sunitinib. The study was stopped early when the benefits of Sunitinib were realized.
Progression free survival of Sunitinib was 11.4 months and placebo 5 months
10% of the patients in Sunitinib group died and 25% in pacebo group. Hazard ratio 0.4%